Phase 4
N=28
Novel Pharmacotherapy Approaches in Smokers With Serious Mental Illness
Bipolar Disorder · Schizophrenia · Schizoaffective Disorder · Nicotine Dependence
Bottom Line
View on ClinicalTrials.gov: NCT04011280 ↗Enrolled (actual)
28
Serious AEs
3.6%
Results posted
Jun 2023
Primary outcome: Primary: Feasibility of Combining ACT With 2 Different Varenicline-assisted Quitting Strategies — 1; 1; 9; 12 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Varenicline (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of California, San Diego
- Primary completion
- Mar 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Feasibility of Combining ACT With 2 Different Varenicline-assisted Quitting Strategies |
1; 1; 9; 12; 13; 12 | — |
Summary
Approximately 60 chronic smokers with bipolar disorder, schizophrenia or schizoaffective disorder who are motivated to try to quit smoking will be randomized to receive smoking cessation treatment with the FDA-approved medication, varenicline, delivered either a) at its standard dose and titration schedule (half of the participants) versus b) at a lower dose and slower titration schedule (the other half), for 12 weeks. All smokers will choose a target quit date sometime between 8 to 35 days after starting the medication. All participants will receive ten 30-minute sessions of a behavioral treatment called Acceptance and Commitment Therapy (ACT). Participants will be followed for an additional 12 weeks off study medication. The major endpoint is the feasibility of combining ACT with the different dosing strategies. Investigators will also conduct a blood test that measures the breakdown of nicotine in the body to explore whether that measure influences treatment response and side effects.
Eligibility Criteria
Inclusion Criteria
- 18-70 years of age
- Outpatients with a DSM-V diagnosis of Bipolar Disorder or Schizophrenia Spectrum Disorder
- Smoke at least 10 cigarettes per day and have an expired carbon monoxide (CO) breathalyzer of ≥ 10 ppm at screening and baseline visits
- Are motivated to quit smoking
- Have access to a mental health provider
Exclusion Criteria
- Females who are pregnant, planning to become pregnant, or lactating
- Test positive for any non-prescribed medications or illicit drugs
- Have made a suicide attempt or engaged in self-mutilatory behavior in the past year
- Meet criteria for another Substance Use Disorder in the past month
- In the investigators' judgement, are either psychiatrically or medically unstable to safely participate
- Are currently using any other form of treatment for smoking cessation
Data sourced from ClinicalTrials.gov (NCT04011280). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.